A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.
|Number of pages||3|
|Journal||American journal of hematology|
|State||Published - Jul 1 2006|
- Acute myeloid leukemia
- Myelodysplastic syndromes